Wearing a Compression Garment for Patients With Hypermobility Type of Ehlers-Danlos Syndrome

NCT02144532 | Completed

• 1 other identifier: 2012-755
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

The Ehlers-Danlos syndrome (EDS) is a rare genetic disease caused by an anomaly of the connective tissue. This syndrome has different forms. Hypermobility type is the most common. It is characterized by generalized joint hypermobility, associated with a chronic pain syndrome. Pains appear as the most frequent demonstration of this syndrome, the worst lived and the most crippling. Faced with insufficient effect of drug treatment, other alternatives have been proposed to relieve these patients. Compression garments have been developed. They appear as medical devices targeted specifically for patients with hypermobility EDS type: in the symptomatic treatment of joint pain, in stabilizing joints by proprioceptive effect and of muscle globulization, and in the functional improvement. The VETCOSED study is a quasi-experimental study of type "Before / After", monocentric, open. The study is realized in the Centre Médico-Chirurgical et de Réadaptation des Massues - Croix Rouge Française de Lyon, in association with the Pôle Information Médicale Evaluation Recherche des Hospices Civils de Lyon. This study concerns about 40 patients with EDS hypermobility type, which will be followed for 8 weeks: 4 weeks during which they will wear a compression custom-made garment (short-sleeved vest CICATREX SED®), and 4 weeks during which they do not carry this garment. The main objective is to demonstrate the effectiveness of compression garments in the EDS hypermobility type, especially in terms of symptomatic improvement joint pain. The main outcomes expected of this study are:

• an improvement of the power and the peaks of couple of muscles rotators of shoulders.
• a decrease of the pains and the defects of articular stability of the shoulder
• an improvement of the quality of life and the functional independence of these patients

Conditions

Ehlers-Danlos Syndrome Hypermobility Type

Keywords

Ehlers-Danlos syndrome; hypermobility; Compression garment; pain; isokinetic evaluation

Outcome Measures

Primary Outcomes (1)

• Power (in watts) of the external rotators of the shoulder of the dominant arm measured by concentric isokinetic evaluation at a constant angular velocity of 180 °/s

  The evaluations will be conducted 3 times: * at the inclusion (D0) * at the end of the BEFORE phase (4 weeks with the compression garment: D0 + 28) * at the end of the AFTER phase (4 weeks without the compression garment: D0 + 56) For each measurement, evaluations will be made with then without the compression garment.

  2 months follow-up

Secondary Outcomes (4)

• Level of pain expressed in the shoulders of patients

  D0,D28,D56

• Score of quality of life measured by the medical outcomes study Short-Form General Health Survey (SF-36 scale)

  D0,D28,D56

• Score of satisfaction measured by the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST)

  D0,D28,D56

• Functional independence score measured by Health Assessment Questionnaire (HAQ)

  D0,D28,D56

Study Arms (1)

Patients with EDS hypermobility type

EXPERIMENTAL

Patients with EDS hypermobility type wearing compression garment then compression garment removal

Device: short-sleeved vest CICATREX SED®)

Interventions

short-sleeved vest CICATREX SED®) DEVICE

Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).

Patients with EDS hypermobility type

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ehlers-Danlos syndrome hypermobility type confirmed the diagnosis of a geneticist
• with an instability of one or both shoulders, painful or considered invalidating by the patient (recurrent dislocation or subluxation : at least once / month or at least 12 times / year)
• having a joint hypermobility syndrome (abnormal mobility and in a non-physiological axis), with a Beighton score of greater than or equal to 5 of 9
• age greater than or equal to 18 years
• size greater than or equal to 1 m 40
• sufficient understanding of the French language in order to respond to self-report questionnaires

You may not qualify if:

• hyperalgic episode in progress
• unstable cardiac disease
• previous history of shoulder surgery
• severe skin lesions,
• pregnancy in progress

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Médecine Physique et de Réadaptation, Centre Médico-Chirurgical de Réadaptation des Massues - Croix-Rouge française

Lyon, 69322, France

Location

MeSH Terms

Conditions

Ehlers-Danlos syndrome type 3; Ehlers-Danlos Syndrome; Pain

Condition Hierarchy (Ancestors)

Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Hemorrhagic Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Skin Abnormalities; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin Diseases, Genetic; Genetic Diseases, Inborn; Collagen Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Emmanuelle CHALEAT-VALAYER, MD

  Médecine Physique et de Réadaptation, Centre Médico-Chirurgical de Réadaptation des Massues

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 7, 2014
• First Posted: May 22, 2014
• Study Start: May 23, 2014
• Primary Completion: April 5, 2018
• Study Completion: April 5, 2018
• Last Updated: December 19, 2025

Record last verified: 2025-12

Locations

FR (1)